The past decade has witnessed growing scientific and commercial interest in the identification of bioactive oral compounds that mimic or potentiate the effects of exercise, so-called ‘exercise pills’ or ‘exercise mimetics.’ These compounds have, to date, typically targeted...
skeletal muscle in an attempt to stimulate some of the adaptations to exercise induced by endurance training. Accordingly, they fail to impart many of the broad health protecting effects of exercise that are seen in tissues and organs other than skeletal muscle. In the context that multiple integrative regulatory and often redundant pathways have evolved to detect and respond to human movement, here we consider the complex challenges of designing a pill that might mimic the extensive range of exercise benefits. In particular, we consider the limits of the current ‘myocentric’ paradigm given the wide-ranging array of impacts that exercise exerts on atherosclerosis and the cardiovascular system. We discuss the validity and limitations of the concept that low dose cardiovascular polypills, already in large scale trials, may represent one form of cardiovascular exercise mimetic. Finally, given that some calls for an exercise pill stem from a response to the perceived failure of expert advice, evidence-based guidelines and current public health approaches, we explore possible strategies that might address the global rise in inactivity. In the event that a broad spectrum exercise mimetic might ever be developed, we discuss some generic issues related to adoption and adherence of therapeutic interventions.

(Received 6 August 2019; accepted after revision 21 October 2019; first published online 20 November 2019)

Corresponding author J. A. Hawley: Mary Mackillop Institute for Health Research, Level 5, 215 Spring Street, Melbourne 3000, Australia. Email: john.hawley@acu.edu.au

Abstract figure legend Voluntary, dynamic exercise provokes widespread perturbations in multiple tissues and organs (left). In an attempt to mimic the effects of exercise training, compounds have focused on selected skeletal muscle signalling pathways (right), ignoring many of the health-protecting effects of exercise in other organs and tissues, such as the heart.

Introduction

Physical inactivity is the fourth leading cause of death globally, with almost one-third of the world’s population failing to meet the minimum prescription for health benefit (Hallal et al. 2012). The universal burden of physical inactivity is mounting, with 6–10% of all deaths from non-communicable diseases worldwide attributable to physical inactivity, a figure that rises to 30% for conditions such as ischaemic heart disease (Lee et al. 2012). Recognizing the proven benefits of exercise on numerous health outcomes (Ruegsegger & Booth, 2018) and the trend towards increasing inactivity worldwide (Guthold et al. 2018), the past decade has witnessed growing scientific and commercial interest in the identification of bioactive oral compounds that mimic or potentiate the effects of exercise, so-called ‘exercise pills’ or ‘exercise mimetics.’

The idea of taking a pill (or pills) to acquire the benefits of exercise in the absence of physical movement and energy expenditure has mass appeal for many sedentary individuals who, for a variety of reasons, do not obtain sufficient physical activity to improve their general health. It may also be attractive for ‘big pharma’ to view physical inactivity as a market to be medicalized for profit. But is an exercise pill a bioplasurable, realistic or desirable goal? In this review we will discuss what is meant by an exercise pill/mimetic, with a view to expanding our understanding of the impact of human movement beyond its effects on skeletal muscle signalling pathways. We will consider the challenges of designing a pill that can mimic the impacts of exercise, given the multitude of signalling networks that have evolved to detect and respond to movement. Finally, given that some calls for an exercise pill reflect a genuine cri de coeur response to the failure of expert advice, evidence-based guidelines and current public health approaches, we consider what might work to reverse our contemporary devolutionary indolence.

What do we mean when we talk about exercise mimetics?

Considerable debate has centred around the nomenclature of what constitutes an ‘exercise pill’ or an ‘exercise mimetic,’ and a number of opinion pieces have weighed in on this topic (Goodyear, 2008; Richter et al. 2008; Warden & Fuchs, 2008; Booth & Laye, 2009; Carey & Kingwell, 2009; Church & Blair, 2009; Hawley & Holloszy, 2009; Fan et al. 2013; Craig et al. 2015; Wall et al. 2016; Fan & Evans, 2017; Guerrieri et al. 2017; Li & Laher, 2017; Weihrauch & Handschin, 2018). In the interests of space, we have summarized the main issues discussed in these commentaries with a view to informing a broader future dialogue.

First, and fundamentally, the use of the term ‘exercise pill’ or ‘exercise mimetic’ is a misnomer, inaccurate and misleading (Booth & Laye, 2009; Booth & Hawley, 2015). Exercise training provokes widespread perturbations in numerous cells, tissues and organs, conferring multiple health-promoting benefits, and it is the multiplicity and complexity of these responses and adaptations that make it highly improbable that any single pharmacological
approach could ever mimic such wide-ranging effects (Hawley et al. 2014). The term ‘exercise mimic’ should arguably be used to refer to interventions that simulate the broad array of adaptations and health benefits of exercise, recognizing the complex integrative physiological responses throughout the body that occur in response to exercise (Booth & Laye, 2009). The simplistic use of the term ‘exercise mimic’ in this context creates unrealistic, if highly marketable, exaggeration of putative benefit. Current pharmacological compounds that purport to be ‘exercise mimetics’ (Narkar et al. 2008; Guerrieri et al. 2017; Choi et al. 2018; Amoasii et al. 2019) activate only a limited number of metabolic networks within skeletal muscle, without addressing impacts on atherosclerosis, the cardiovascular system or indeed other organ systems impacted by exercise. As such, terminology to describe the effect of any oral compound that purports to have ‘exercise-like’ properties should be focused on the narrow range of biological pathway(s) activated by any given agent, so that the specificity and limited response to that drug are accurately defined (Booth & Laye, 2009; Carey & Kingwell, 2009).

A second issue arising directly from the imprecise nomenclature surrounding exercise pills/mimetics is the generic use of these terms, with no appreciation or insight given to distinct biological adaptations that occur in response to different modes of exercise (e.g. endurance-versus strength-based, or concurrent training) and their divergent effects (i.e. increased oxidative capacity and fatigue resistance, muscle hypertrophy and strength). As such, the general public could be excused for thinking that exercise mimetics are a ‘one pill fits all’ and that the benefits of all types of exercise can be obtained from a single compound. This is a spurious notion that ignores the complexity and variability of both human adaptation (e.g. high versus low responders), and also the science underpinning exercise prescription for optimization of benefit. Whilst there has been an almost exclusive focus on discovering molecules that activate skeletal muscle pathways promoting an ‘oxidative/endurance phenotype’, little scientific enquiry has been devoted to compounds that could stimulate networks that preserve other aspects of systemic health, such as cardiovascular function (discussed subsequently). Realistically, what single pill could simultaneously increase skeletal muscle oxidative capacity and endurance, improve muscle strength and function, stimulate cardiovascular remodelling and enhance autonomic nervous system function?

The problem of reductionism in the context of exercise mimetics

One thing we have learnt from the results of studies utilizing knockout animals is that no single ‘exercise gene’ or pathway exists (Booth & Laye, 2009) and that redundancy is a characteristic of complex human integrative systems (Joyner, 2011; Hawley et al. 2014). For example, the discovery of the inducible coactivator, the peroxisome proliferator-activated receptor-γ coactivator (PGC-1α) in 1999 heralded a major breakthrough in unravelling the cellular events that promote mitochondriogenesis (Wu et al. 1999). Subsequent observations that many mitochondrial genes were reduced in PGC-1α knockout mice, and that muscle-specific overexpression of PGC-1α activated genetic programmes characteristic of slow-twitch muscle fibres (Lin et al. 2002), and improved endurance running capacity (Calvo et al. 2008), led to the assumption that PGC-1α was the ‘master regulator’ of mitochondrial biogenesis (Wu et al. 2002). However, later work revealed that exercise-trained PGC-1α knockout mice still had all or many of the normal endurance-based exercise adaptations (Leick et al. 2008; Rowe et al. 2012), suggesting that PGC-1α was not mandatory for exercise training-induced increases in skeletal muscle mitochondrial proteins. Of course, the fact that PGC-1α is not necessary does not exclude that targeting the pathway might be a good thing.

The multiple and often redundant responses associated with exercise (Hawley et al. 2014), the diverse signalling kinases that respond to these stimuli (Hoffman et al. 2015), the numerous downstream pathways and targets (Egan et al. 2016), and the complex spatial and temporal interactions between the various elements that combine to produce the integrated response to an exercise challenge (Bassel-Duby & Olson, 2006) make it highly improbable that there would ever exist a single putative regulator driving any exercise phenotype. Indeed, a common feature of the so-called ‘master regulators’ of metabolism (e.g. PGC-1α) is that they are highly versatile, interacting with many different transcription factors to activate distinct biological programmes in different tissues (Lin et al. 2005). It is this very versatility that make these biological nodes of regulation a double-edged sword, with their ultimate efficacy as therapeutic targets dependent on the ability to achieve biological and tissue specificity (Puigserver & Spiegelman, 2003). The recent discovery that contracting muscle releases myokines (Fig. 1) and is involved in ‘cross-talk’ with other organs/tissues (adipose tissue releases adipokines in a similar fashion) also adds a level of complexity to any discussion of drugs/compounds to mimick or potentiate the effects of exercise (Eckel, 2019). Indeed, secretomic studies of muscle cells have shown the presence of hundreds of myokines (Hartwig et al. 2014), most of which have unknown functions. In addition to myokines, metabolites released by contracting skeletal muscle play an important role as ‘exercise factors’ that fine-tune metabolic control. Such multiplicity, in our opinion, makes it highly unlikely that such metabolic cross-talk could be evoked by artificial compounds.
A third issue is that maintaining a drug-induced ‘metabolic overdrive’ for sustained periods could have potentially deleterious health effects (Weihrauch & Handschin, 2018), as constant activation of ‘exercise pathways’ can induce a chronic catabolic state due to the inhibition of protein synthesis and activation of autophagy (e.g. activation of AMPK and the inhibition of the mammalian target of rapamycin, mTOR, a key regulator of protein turnover). The foundations for exercise-induced adaptation are episodic periods of metabolic overload, followed by adequate rest/recovery for restoration of muscle substrates, muscle repair and the regeneration necessary for any adaptation to occur. We are not aware of any evidence that pharmacological compounds could mimic such effects, although it may be theoretically possible to do so. The variability observed between humans in response to any drug, along with consideration of the optimal dose or doses required to maintain activation/repression of targeted biochemical pathways, make long-term prescription of an exercise pill/mimetic problematic and challenging, just as it does for existing drug approaches. This scenario is exacerbated if several ‘mimetics’ need to be taken simultaneously. As suggested by Spiegelman (2018), perhaps specific pathways induced by exercise can be dosed well beyond what is naturally produced during exercise, a challenge taken up by the NIH through the recent launching of its programme ‘Molecular Transducers of Physical Activity.’

What do we want from an exercise mimetic? Why is exercise worth mimicking?

It is puzzling that the focus of exercise mimicry has been on promoting mitochondrial biogenesis in skeletal muscle, when there is a much larger and more compelling landscape for the benefits of exercise in humans (see Fig. 2). The global causes of disease study reported around half of the top 15 causes of death worldwide possess

![Diagram of Exercise Mimetics and Their Effects](image-url)

**Figure 1.** Multiple tissues and organ systems are affected by exercise, initiating diverse homeostatic responses

The majority of exercise mimetics have targeted metabolic networks within skeletal muscle (left panel). The discovery of muscle ‘cross-talk’ with multiple organs including adipose tissue, liver, pancreas, bone and the brain (right panel), has provided exercise biologists with a mechanistic framework for understanding how exercise mediates many of its beneficial whole-body effects on health. While some myokines exert their actions on other organs in an endocrine fashion, others operate locally on skeletal muscle and thereby provide a feedback loop for the muscle to regulate its own growth and regeneration for adaptation to exercise training. In addition, muscle energy status (i.e. glycogen) exerts profound effects on acute regulatory processes underlying gene expression and cell signalling. As such, nutrient–exercise interactions have the potential to upregulate many biochemical pathways with putative roles in training adaptation. It is highly unlikely that any exercise pill/mimetic or combinations thereof could ever replicate the widespread effects of exercise on other organs/tissues, or respond to changes in the prevailing muscle fuel stores.
Figure 2. Central (cardiovascular) and peripheral (skeletal muscle) adaptations to exercise training
Cardiovascular adjustments to exercise (upper panel) require an intact autonomic nervous system and are driven by three major signals: (1) feedforward "central command" related to motor output, which activates selected areas in the brainstem cardiovascular (and respiratory) centres to stimulate increases in heart rate, blood pressure and ventilation; (2) afferent feedback from thinly myelinated and unmyelinated type III and IV afferents in contracting muscles that increase sympathetic activation; and (3) baroreceptors in the carotid sinus and aortic arch that provide...
an atherosclerotic aetiology, including ischaemic heart disease and cerebrovascular disease, dementia, diabetes, kidney disease and hypertension (GBD 2015 Mortality and Causes of Death Collaborators, 2016). In all cases, the age-related incidence of these diseases decreased in the decade between 2005 and 2015, yet global impact increased due to changes in population ageing and growth. Additionally, there is at least some emerging evidence that age-specific rates of atherosclerotic disease are once again on the rise in countries like the United States that have had high levels of obesity for many years (Khan et al. 2018). Whilst not dismissing the impacts of exercise on skeletal muscle, perhaps a more compelling question is ‘to what extent might an exercise mimetic benefit the cardiovascular system?’ Specifically, since each of these end-organ manifestations is largely related to a common disease process, what effects could an exercise mimetic have on the most common, costly and deadly global disease in the modern world, namely atherosclerosis?

Atherosclerosis is a disease that begins in the first decade of life (Enos et al. 1955; Stary, 1989; Tuzcu et al. 2001), with important genetic and intra-uterine pre-determinants. It is detected extremely late and contemporary management largely treats it as a problem limited to isolated organs or focal lesions (Kannel et al. 1998; Fox et al. 2004; Smolina et al. 2012). It is a systemic disease (Stone et al. 2011), so exercise is an appealing therapy because it has systemic effects (Green et al. 2002), and it can be applied in an early prevention context (Watts et al. 2004). Importantly, exercise has both direct and indirect benefits in terms of the health of the heart and the artery walls (Green et al. 2008).

Early literature on the cardiovascular benefits of exercise focused on the effects of exercise on cardiovascular risk factors; that is, artery health was perceived as being a consequence of the impact that modification of risk factors exerts in the vessel wall. In general, these studies found that exercise had beneficial effects on individual risk factors and that the magnitude of benefit depended upon the nature of the patients (e.g. raised risk factors at entry or relatively healthy, young or old, male or female) and the nature of the intervention (endurance or resistance training, high or low intensity, duration, frequency, etc.). A general conclusion from this vast body of research is that, although, on average, exercise has beneficial effects on reducing risk, the magnitude of exercise-induced benefit is modest compared to the gains achieved from pharmacological therapy (e.g. statins, angiotensin converting enzyme inhibitors [ACEI], angiotensin receptor blockers [ARB]) (Thompson et al. 2003). This is not to suggest that exercise is an inferior intervention, especially since it can be considered a ‘polypill’ capable of modifying multiple risk factors at once (Joyner & Green, 2009). However, for each individual risk factor, with the possible exception of exercise versus metformin for diabetes prevention (though not treatment), the drugs typically ‘win’. Why not simply treat each risk factor using the blockbuster drug? Or better yet, develop a drug combination (pharma polypill) to get the job done?

If exercise is a cardiovascular polypill, is a pharmacological polypill a better strategy?

If we broaden the concept of an exercise mimetic beyond skeletal muscle mitochondrial adaptations to include its impacts on the cardiovascular system, perhaps we already have a form of exercise mimetic? The concept that a polypill containing low doses of several compounds might afford broad-based protection was first proposed in the early 2000s (Wald & Law, 2003). Such a polypill would include compounds that lower blood lipids, reduce blood pressure, are anti-thrombotic, blunt autonomic responses, and lower blood glucose concentration. The argument for such a polypill is that in large randomized clinical trials, low doses of many drugs in these classes have minimal side effects, but when administered together they would act synergistically to reduce mortality from cardiovascular disease. Such a polypill would also activate many of the protective factors and mechanisms (both traditional and non-traditional) engaged by exercise (Fiuza-Luces et al. 2013), with skeletal muscle mitochondrial biogenesis being an obvious exception to this assertion (see below).

Along these lines, the original polypill modelling by Wald and Law (2003) asserted that ‘The Polypill strategy could largely prevent heart attacks and stroke if taken by everyone aged 55 and older and everyone with existing cardiovascular disease. It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than any other single intervention.’ Recent clinical trials have shown that the magnitude of risk factor reduction evoked by short term use of a polypill (~80%) is similar to those predicted in the original modelling paper (Wald et al. 2012). Retrospective analyses on a suite of polypill compounds...
suggest improved long-term survival after acute coronary syndrome or myocardial infarction (Oliveras Vila et al. 2014). Parenthetically, individuals in Sweden who have persistently advantageous risk factor profiles across a 20 year period (low blood pressure, physically active, appropriate diet, non-smokers) exhibited an 80% lower risk of myocardial infarction than those who possess none of these virtues (Akesson et al. 2014). A similar analysis in the USA revealed a > 12 year longevity benefit beyond the age of 50 years for those in the virtuous grouping (Li et al. 2018). A recent primary and secondary prevention trial of a low dose polypill in 6838 subjects aged 40–75 years found a 40% reduction in the risk of major cardiovascular events in individuals without a prior history of cardiovascular disease. Adherence based on blister pack count was generally excellent (80%) and adverse events were low. In a subgroup with even higher adherence, the reduction in events was close to 60%. These findings may, if anything, be an underestimate of benefit, since the comparator group received a healthy lifestyle education intervention (Roshandel et al. 2019).

These observations are consistent with the potential for a marked decrease in mortality with broad based use of the cardiovascular polypill strategy. If the goal of an exercise mimetic is to improve cardiometabolic risk among individuals who cannot or will not exercise, then a polypill approach may be considered a viable and well tolerated alternative. Additionally, it is clearly possible to formulate such a polypill with already approved and extremely low-cost components designed for once per day dosing.

Can a polypill or exercise mimic activate evolutionary pathways geared to detect movement?

An unanswered question is whether the addition of exercise to a low-dose polypill that emulates exercise-like effects on cardiovascular risk factors can provide additive benefit. We speculate that this may indeed be the case, given the existence of a ‘risk factor gap’. In the mid-2000s we pointed out that the beneficial effects of physical activity, in terms of its impact on all-cause and cardiovascular mortality, could not be fully accounted for by considering the effects on cardiovascular risk factors (Green et al. 2008; Joyner & Green, 2009). Whilst it is generally accepted that humans who have high levels of either occupational or recreational physical activity have a 30–40% reduction in both all-cause and cardiovascular mortality (Morris et al. 1953; Blair & Morris, 2009; Moore et al. 2012), physical activity and/or exercise training have relatively modest effects on traditional risk factors (lipids, blood pressure, glucose concentrations) associated with cardiovascular disease (Thompson et al. 2003). The cumulative effect of physical activity and/or exercise on these risk factors explains only 30–50% of the reductions in all-cause and cardiovascular mortality seen as a result of physical activity (Mora et al. 2007; Hamer & Stamatakis, 2009).

Because a substantial fraction of the protective effects of exercise are unaccounted for by modification in traditional risk factors, other mechanisms must be invoked to explain the unexplained positive effects of exercise on mortality. The possible additional effects of exercise on key protective mechanisms include: (1) improved endothelial function which is anti-atherogenic, pro-vasodilatation, anti-inflammatory and anti-thrombotic; (2) remodelling and increased size of large blood vessels like the coronary arteries along with increased collateral circulation; (3) improved autonomic balance to the heart which likely has anti-arrhythmic effects; and (4) psychological effects related to mood and autonomy. In this context, for an exercise mimic to emulate the cardiovascular effects of exercise it would have to have broad based effects on cardiovascular risk factors, and also mimic exercise effects on other organ and regulatory systems.

Can a polypill that targets risk factors fully mimic the cardiovascular benefits of exercise?

The Nobel prize-winning discoveries showing that endothelial cells produced paracrine hormones with myriad anti-atherogenic effects introduced the important concept that exercise, by virtue of its impacts on the movement of the blood, has direct effects on artery health and atherosclerotic risk (Green et al. 2017). Endothelial cells detect shear stress forces that trigger their activation (Pohl et al. 1986; Berdeaux et al. 1994; Dawson et al. 2010; Gielen et al. 2010). If the shear stimulus is episodically repeated, then chronic adaptation occurs with upregulation of paracrine generating systems (Green et al. 2004). In this way, increases in blood movement is a trigger or stimulus to upregulation of endothelial function which, in turn, is anti-atherogenic by virtue of impacts of platelet adhesion and activation, transmigration of monocytes to the subintimal space, decreased macrophage transformation, decreased smooth muscle cell proliferation, and transmigration and anti-oxidant impacts which diminish low-density lipoprotein oxidation and foam cell formation. Longer term shear stress-mediated activation of the endothelium induces structural remodelling of the artery wall, favouring enhanced blood flow (Langille & O’Donnell, 1986; Green et al. 2017).

Although distinct forms of shear stress can induce distinct types of artery functional and structural adaptation (Thijssen et al. 2009; Newcomer et al. 2011), in general it is accepted that episodic increases in shear are highly beneficial in terms of arterial health. Whilst shear forces can be induced through contrived laboratory means such as repeated heating (and this has beneficial effects of artery function and health (Green et al. 2010;
Naylor et al. (2011), the most common form, indeed the natural and evolutionary stimulus that triggers arterial shear stress, is human movement. This is an important point in the context of those who would propose an exercise mimetic. If humans have evolved detector mechanisms that are based on motion, such as the movement of blood across endothelial cell membranes, how does one mimic such pathways in a resting individual who is administered a pill? Indeed, endothelial activation and adaptation is but one example of a physiological system based on the detection of a biophysical stimulus. Arteries are also sensitive, and adapt to, changes in transmural wall pressure (Atkinson et al. 2015), whilst specialized cardiopulmonary and arterial baroreceptors monitor blood pressure and induce autonomic responses (baroreflexes). Ergoreceptors trigger cardiovascular responses in skeletal muscle, whilst the heart itself responds to changes in chamber loading conditions (volume and pressure) by modifying its function and remodelling (Spence et al. 2011).

Several truths emerge for those who enthusiastically promote the merits of an exercise pill on the basis of substances that solely mimic muscle-centric effects. Exercise is not simply a stimulus for upregulating metabolic pathways in skeletal muscle, but, instead, has widespread effects on multiple organ systems including myriad impacts on the cardiovascular system. The arteries and the heart are end-organs in terms of the impact of exercise; they do not simply benefit from skeletal...
muscle serfdom. Exercise is a stimulus that directly affects cardiovascular function and, by virtue of this, arterial and cardiac adaptation. This occurs indirectly because exercise modifies risk factors in ways that enhance endothelial and cardiac function, but also more directly because changes in systemic haemodynamics are directly sensed and responded to by cardiovascular structures, including those in the walls of the arteries and the heart.

**What evidence is there that humans would adhere to taking an exercise pill, or multiple pills?**

The preceding discussion highlights the fact that, as a consequence of the blockbuster era of drug development that occurred from the 1980s to the 2000s, we have highly effective medications for the treatment of blood pressure (ACEI, ARB), cholesterol (statins) and clotting. Thanks to the pharma-driven profit motive, the evidence-based benefits of these medications are extremely well known. Yet there is clear evidence that adherence to these medications is very poor: among patients with chronic illness, there is clear evidence that adherence to these medications benefits of these medications are extremely well known. Yet to the pharma-driven profit motive, the evidence-based (ACEI, ARB), cholesterol (statins) and clotting. Thanks to the pharma-driven profit motive, the evidence-based benefits of these medications are extremely well known. Yet there is clear evidence that adherence to these medications is very poor: among patients with chronic illness, approximately 50% or more of patients do not take medications as prescribed (Brown & Bussell, 2011). This may partly be due to perceived or under-appreciated side effects (e.g. myalgia for statins), the cost of lifelong commitment to prescription and/or the complexity of managing multi-drug prescriptions. It is worth noting that, in a recent trial of a polypill combining three medications, adherence was excellent compared to that associated with multiple drug regimes (Roshandel et al. 2019). This point is germane for those advocating the development of an exercise pill, or pills, when these would need to be added to the existing multiple-drug regimens common in patients with chronic diseases. In the context of adherence and tolerability, it is also worth noting that the vast majority of skeletal muscle mimetics to date have not been tested in humans, with knowledge of the effects of these compounds on biomarkers of health and exercise capacity based entirely on preclinical findings in rodents (Li & Laher, 2017). In several cases, severe side effects associated with some of the first-generation ‘mimetics’ have precluded their further clinical development (Fan & Evans, 2017). Whether the outcomes observed in animal models (using reductionist ‘loss-of-function and/or gain-of-function’ approaches) translate into humans is a leap of faith.

In summary, increasing the effectiveness of adherence to existing evidence-based and highly effective medications would, arguably, have a greater impact on the health of the population than the invention and addition of another pill, or multiple pills, to ‘cure’ inactivity. In the context that less than half of patients with chronic diseases currently adhere to their multi-drug regimes, it seems a flawed strategy to add further drugs that mimic exercise; the addition of multiple ‘exercise mimetics’ necessary to mimic the broad spectrum of impacts of exercise in multiple organ systems is even more problematic.

Finally, the issues raised in this section reveal a logical sinkhole for those who would promote a pharmacological fix for behavioural problems. Ergo: let’s fix a behavioural issue, inactivity, using a pill! But people are likely to be resistant to taking our new drug. Let’s fix non-adherence to taking pills, a behavioural issue, with a new pill...? What evidence do the proponents of the development of a pill to fix a behavioural problem, inactivity, have that people would behave well enough to adhere to it? Would these proponents also recommend the development of a drug that manages another behavioural issue, drug adherence, with a new drug aimed at making people compliant with advice to take their medications?

**Where to from here?**

In this review we have discussed the biological and cultural limitations of the current skeletal muscle-centric focus on exercise mimetics. Whilst able to mimic some of the health aspects of exercise, such mimetics present a narrow perspective in the fight against the inactivity epidemic and ignore the complex adaptive responses associated with many forms of exercise in multiple organ systems. At best, they might represent a partial exercise mimetic. From a cultural and behavioural perspective, a host of issues related to adoption and adherence that plague almost every therapeutic intervention are likely to be at play should an exercise pill ever be developed (see Fig. 3). In this context, a focus on so-called low-agency interventions that promote physical activity seems like an attractive strategy (Adams et al. 2016). The extent to which the political will exists to implement evidence-based strategies remains to be demonstrated.

**References**

Adams J, Mytton O, White M & Monsivais P (2016). Why are some population interventions for diet and obesity more equitable and effective than others? The role of individual agency. *PLoS Med* **13**, e1001990.

Akesson A, Larsson SC, Discacciati A & Wolk A (2014). Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. *J Am Coll Cardiol* **64**, 1299–1306.

Amosii L, Sanchez-Ortiz E, Fujikawa T, Elmquist JK, Bassel-Duby R & Olson EN (2019). NURR1 activation in skeletal muscle controls systemic energy homeostasis. *Proc Natl Acad Sci U S A* **116**, 11299–11308.

Atkinson CL, Carter HH, Naylor LH, Dawson EA, Marusic P, Hering D, Schlaich MP, Thijssen DH & Green DJ (2015). Opposing effects of shear-mediated dilation and myogenic constriction on artery diameter in response to handgrip exercise in humans. *J Appl Physiol* (1985) **119**, 858–864.
Bassel-Duby R & Olson EN (2006). Signaling pathways in skeletal muscle remodeling. *Ann Rev Biochem* **75**, 19–37.

Berdeaux A, Ghaleh B, Dubois-Rande JL, Vigue B, Drieu La Rochelle C, Hittinger L & Giudicelli JF (1994). Role of vascular endothelium in exercise-induced dilatation of large epicardial coronary arteries in conscious dogs. *Circulation* **89**, 2799–2808.

Blair SN & Morris JN (2009). Healthy hearts – and the universal benefits of being physically active: physical activity and health. *Ann Epidemiol* **19**, 253–256.

Booth FW & Hawley JA (2015). The erosion of physical activity in Western societies: an economic death march. *Diabetologia* **58**, 1730–1734.

Booth FW & Laye MJ (2009). Lack of adequate appreciation of physical exercise’s complexities can pre-empt appropriate design and interpretation in scientific discovery. *J Physiol* **587**, 5527–5539.

Brown MT & Bussell JK (2011). Medication adherence: WHO cares? *Mayo Clin Proc* **86**, 304–314.

Calvo JA, Daniels TG, Wang X, Paul A, Lin J, Spiegelman BM, Stevenson SC & Rangwala SM (2008). Muscle-specific expression of PPARγ coactivator-1α improves exercise performance and increases peak oxygen uptake. *J Appl Physiol (1985)* **104**, 1304–1312.

Carey AL & Kingwell BA (2009). Novel pharmacological approaches to combat obesity and insulin resistance: targeting skeletal muscle with ‘exercise mimetics’. *Diabetologia* **52**, 2015–2026.

Choi SH, Bylykbashi E, Chatila ZK, Lee SW, Pulli B, Clemenson GD, Kim E, Rompala A, Oram MK, Asselin C, Aronson J, Zhang C, Miller SJ, Lesinski A, Chen JW, Kim DY, van Praag H, Spiegelman BM, Gage FH & Tanzi RE (2018). Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. *Science* **361**, eaan8821.

Church TS & Blair SN (2009). When will we treat physical activity as a legitimate medical therapy . . . even though it does not come in a pill? *Br J Sports Med* **43**, 80–81.

Craig DM, Ashcroft SF, Belew MY, Stocks B, Currell K, Baar K & Philp A (2015). Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. *Front Physiol* **6**, 296.

Dawson EA, Rathore S, Cable NT, Wright DJ, Morris JL & Green DJ (2010). Impact of introducer sheath coating on endothelial function in humans after transradial coronary procedures. *Circ Cardiovasc Interv* **3**, 148–156.

Eckel J (2019). Myokines in metabolic homeostasis and diabetes. *Diabetologia* **62**, 1523–1528.

Egan B, Hawley JA & Zierath JR (2016). Snapshot: Exercise metabolism. *Cell Metab* **24**, 342–342.e1.

Enos WF Jr, Beyer JC & Holmes RH (1955). Pathogenesis of coronary disease in American soldiers killed in Korea. *J Am Med Assoc* **158**, 912–914.

Fan W, Atkins AR, Yu RT, Downes M & Evans RM (2013). Road to exercise mimetics: targeting nuclear receptors in skeletal muscle. *J Mol Endocrinol* **51**, T87–T100.

Fan W & Evans RM (2017). Exercise mimetics: Impact on health and performance. *Cell Metab* **25**, 242–247.

Fiuza-Luces C, Garatachea N, Berger NA & Lucia A (2013). Exercise is the real polypill. *Physiology (Bethesda)* **28**, 330–358.

Fox CS, Evans JC, Larson MG, Kannel WB & Levy D (2004). Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. *Circulation* **110**, 522–527.

GBD 2015 Mortality and Causes of Death Collaborators (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* **388**, 1459–1544.

Gieles S, Schuler G & Adams V (2010). Cardiovascular effects of exercise training: molecular mechanisms. *Circulation* **122**, 1221–1238.

Goodyear LJ (2008). The exercise pill. Too good to be true? *N Engl J Med* **359**, 1842–1844.

Green DJ, Carter HH, Fitzsimons MG, Cable NT, Thijsse DN & Naylor LH (2010). Obligatory role of hyperaemia and shear stress in microvascular adaptation to repeated heating in humans. *J Physiol* **588**, 1571–1577.

Green D, Cheetham C, Madratt L, Watts K, Best M, Taylor R & O’Driscoll G (2002). Effect of lower limb exercise on forearm vascular function: contribution of nitric oxide. *Am J Physiol Heart Circ Physiol* **283**, H189–H1907.

Green DJ, Hopman MT, Padilla J, Laughlin MH & Thijsse DN (2017). Vascular adaptation to exercise in humans: role of hemodynamic stimuli. *Physiol Rev* **97**, 495–528.

Green DJ, Maiorana A, O’Driscoll G & Taylor R (2004). Effect of exercise training on endothelium-derived nitric oxide function in humans. *J Physiol* **561**, 1–25.

Green DJ, O’Driscoll G, Joyner MJ & Cable NT (2008). Exercise and cardiovascular risk reduction: time to update the rationale for exercise? *J Appl Physiol (1985)* **105**, 766–768.

Guerrreri D, Moon HY & van Praag H (2017). Exercise in a pill: The latest on exercise-mimetics. *Brain Plast* **2**, 153–169.

Guthold R, Stevens GA, Riley LM & Bull FC (2018). Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. *Lancet Glob Health* **6**, e1077–e1086.

Hallal PC, Andersen LB, Bull FC, Guthold R, Kyu HH, Adamo KB, Guron MF & Haskell W (2018). Global physical activity levels: surveillance progress, trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. *Lancet Glob Health* **6**, e1077–e1086.

Hamer M & Stamatakis E (2009). Physical activity and risk of cardiovascular disease events: inflammatory and metabolic mechanisms. *Med Sci Sports Exerc* **41**, 1206–1211.

Hartwig S, Raschke S, Knebel B, Scheler M, Irmler M, Passlack W, Muller S, Hanisch FG, Franz T, Li X, Dicken HD, Eckardt K, Beckers J, de Angelis MH, Weigert C, Harig HU, Al-Hasani H, Ouwens DM, Ekel J, Kotzka J & Lehr S (2014). Secretome profiling of primary human skeletal muscle cells. *Biochim Biophys Acta* **1844**, 1011–1017.

Hawley JA, Hargreaves M, Joyner MJ & Zierath JR (2014). Integrative biology of exercise. *Cell* **159**, 738–749.

Hawley JA & Holloszy JO (2009). Exercise: it’s the real thing! *Nutr Rev* **67**, 172–178.
Exercise mimetics

Hoffman NJ, Parker BL, Chaudhuri R, Fisher-Wellman KH, Kleinert M, Humphrey SJ, Yang P, Holliday M, Trefely S, Fazakerley DJ, Stöckli J, Burchfield JG, Jensen TE, Jothi R, Kiens B, Wojtaszewski JF, Richter EA & James DE (2015). Global phosphoproteomic analysis of human skeletal muscle reveals a network of exercise-regulated kinases and AMPK substrates. Cell Metab 22, 922–935.

Joyner MJ (2011). Giant sucking sound: can physiology fill the intellectual void left by the reductionists? J Appl Physiol (1985) 111, 335–342.

Joyner MJ & Green DJ (2009). Exercise protects the cardiovascular system: effects beyond traditional risk factors. J Physiol 587, 5551–5558.

Kannel WB, Wilson PW, D’Agostino RB & Cobb J (1998). Sudden coronary death in women. Am Heart J 136, 205–212.

Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, Kannel WB, Wilson PW, D’Agostino RB & Cobb J (1998). Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380, 219–229.

Leick L, Wojtaszewski JF, Johansen ST, Küllerich K, Comes G, Li Y, Pan A, Wang DD, Liu X, Dhana K, Franco OH, Kaptoge S, Li S & Laher I (2017). Exercise mimetics: Running without a road map. Clin Pharmacol Ther 101, 188–190.

Li Y, Pan A, Wang DD, Liu X, Dhana K, Franco OH, Kaptoge S, Di Angelantonio E, Stampfer M, Willett WC & Hu FB (2018). Impact of healthy lifestyle factors on life expectancies in the US population. Circulation 138, 345–355.

Lin J, Handschin C & Spiegelman BM (2005). Metabolic coactivator through the PGC-1 family of transcription coactivators. Cell Metab 1, 361–370.

Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R & Spiegelman BM (2002). Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nature 418, 797–801.

Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki HA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur SM, Hartge P & Lee IM (2012). Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med 9, e1001335.

Mora S, Cook N, Buring JE, Ridker PM & Lee IM (2007). Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 116, 2110–2118.

Morris IN, Heady JA, Raffle PA, Roberts CG & Parks JW (1953). Coronary heart-disease and physical activity of work. Lancet 262, 1053–1057.

Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ & Evans RM (2008). AMPK and PPARγ agonists are exercise mimetics. Cell 134, 405–415.

Naylor LH, Carter H, FitzSimons MG, Cable NT, Thijsen DH & Green DJ (2011). Repeated increases in blood flow, independent of exercise, enhance conduit artery vasodilator function in humans. Am J Physiol Heart Circ Physiol 300, H664–H669.

Newcomer SC, Thijsen DH & Green DJ (2011). Effects of exercise on endothelium and endothelium/smooth muscle cross talk: role of exercise-induced hemodynamics. J Appl Physiol (1985) 111, 311–320.

Oliveras Vila T, Ferrer Massot M, Curos Abadal A, Rueda Sobella F, Serra Flores J, Carrillo Suarez X & Bayes-Genis A (2014). Real-life use of the polypill components (ASA+ACEI+statins) after an acute coronary syndrome and long-term mortality. Int J Cardiol 177, 209–210.

Pohl U, Holtz J, Busse R & Bassenge E (1986). Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 8, 37–44.

Puigserver P & Spiegelman BM (2003). Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr Rev 24, 78–90.

Richter EA, Kiens B & Wojtaszewski JF (2008). Can exercise mimetics substitute for exercise? Cell Metab 8, 96–98.

Roshandel G, Khoshnia M, Pourshoor H, Hemming K, Kamargar F, Ghasemi, Ostovaneh MR, Nateghi A, Majed M, Navabaksh B, Merat S, Poursamsals, Nanlini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadeh N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng FK & Malekzadeh R (2019). Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 394, 672–683.

Rowe GC, El-Khoury R, Pattan IS, Rustin P & Arany Z (2012). PGC-1α is dispensable for exercise-induced mitochondrial biogenesis in skeletal muscle. PLoS One 7, e41817.

Ruegsegger GN & Booth FW (2018). Health benefits of exercise. Cold Spring Harb Perspect Med 8, a029694.

Smolina K, Wright FL, Rayner M & Goldacre MJ (2012). Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 344, d8059.

Spence AL, Naylor LH, Carter HH, Buck CL, Dembo L, Murray CP, Watson P, Oxborough D, George KP & Green DJ (2011). A prospective randomised longitudinal MRI study of left ventricular adaptation to endurance and resistance exercise training in humans. J Physiol 589, 5443–5452.

Spiegelman B (2018). Preface. In Hormones, Metabolism and the Benefits of Exercise, ed. Spiegelman B. Springer, Cham, Switzerland.

Stary HC (1989). Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 9, 119–32.
Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z & Serruys PW; PROSPECT Investigators (2011). A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* **364**, 226–235.

Thijssen DH, Dawson EA, Black MA, Hopman MT, Cable NT & Green DJ (2009). Brachial artery blood flow responses to different modalities of lower limb exercise. *Med Sci Sports Exerc* **41**, 1072–1079.

Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancy AK & Wenger NK; American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention; American Heart Association Council on Nutrition, Physical Activity, and Metabolism Subcommittee on Physical Activity (2003). Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation* **107**, 3109–3116.

Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, Young JB & Nissen SE (2001). High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. *Circulation* **103**, 2705–2710.

Wald DS, Morris JK & Wald NJ (2012). Randomized Polypill crossover trial in people aged 50 and over. *PLoS One* **7**, e41297.

Wald NJ & Law MR (2003). A strategy to reduce cardiovascular disease by more than 80%. *BMJ* **326**, 1419.

Wall CE, Yu RT, Atkins AR, Downes M & Evans RM (2016). Nuclear receptors and AMPK: can exercise mimetics cure diabetes? *J Mol Endocrinol* **57**, R49–58.

Warden SJ & Fuchs RK (2008). Are “exercise pills” the answer to the growing problem of physical inactivity? *Br J Sports Med* **42**, 862–863.

Watts K, Beve P, Siafarikas A, Davis EA, Jones TW, O’Driscoll G & Green DJ (2004). Exercise training normalizes vascular dysfunction and improves central adiposity in obese adolescents. *J Am Coll Cardiol* **43**, 1823–1827.

Weihrauch M & Handschin C (2018). Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls. *Biochem Pharmacol* **147**, 211–220.

Wu H, Kanatous SB, Thurmond FA, Gallardo T, Isotani E, Bassel-Duby R & Williams RS (2002). Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. *Science* **296**, 349–352.

Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC & Spiegelman BM (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell* **98**, 115–124.

**Additional information**

**Competing interests**

The authors have no conflicts of interest to declare.

**Author contributions**

All authors have approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

**Funding**

None.

**Keywords**

AMPK, cardiovascular physiology, exercise mimetics, exercise physiology, PGC-1, skeletal muscle